Tweet
<img alt="" height="1" width="1" />
Roche's MabThera Delays Need for Additional Lymphoma Treatment, Study Says
Bloomberg
Roche Holding AG's MabThera medicine helped keep a common form of blood cancer at bay without the need for additional therapy, a study found. Patients newly diagnosed with advanced follicular lymphoma ...
Genentech, Biogen Reveal Positive Phase III Study Of Rituxan - Quick FactsRTT News
Rituxan delays chemo for slow-growing lymphomaReuters
Phase III Study Showed Rituxan® for Initial Use Followed by Continued Use ...Business Wire (press release)
all 9 news articles »
More...